Sophiris Bio Inc T.SHS

Primary Symbol: SPHS

Healthcare Biotechnology

Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.

EXPM:SPHS - Post by User

Sophiris Bio Inc

Bullboard Posts

Comment by your_solution1on Nov 27, 2012 12:39am

271 Views

Post# 20647117

RE: SHS future could look like this: (NPC)

SHS is right now could be at a point where NPC was in Nov. 2011....see what happened with the progress of the phase III and a short time before before FDA trial. (with Warburg as top investor behind the scene SHS could become a full success) hope my vision is not confusing.... I am glad to know both companies and knowing they are both on the path of success (again they work on different drugs)

https://finance.yahoo.com/echarts?s=SHS.TO+Interactive#symbol=shs.to;range=2y;compare=;indicator=volume;charttype=area;crosshair=on;ohlcvalues=0;logscale=off;source=undefined;

https://finance.yahoo.com/echarts?s=NPC.TO+Interactive#symbol=npc.to;range=2y;compare=;indicator=volume;charttype=area;crosshair=on;ohlcvalues=0;logscale=off;source=undefined;

Bullboard Posts

How one company is disrupting PoC testing